Atrium Therapeutics, Inc.
NASDAQ:RNABiotechnology
+$0.16 today
- Market cap
- $150.57M
- Beta
- 0.42
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$3.78
Volume 0.23M
Average 0.35M
Balance Sheet
Inspect the capital base behind the business.
Assets
$278.35M
FY 2025 · Annual
Liabilities
$71.07M
FY 2025 · Annual
Equity
$207.29M
FY 2025 · Annual
Balance Sheet
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $267.8M |
| Receivables | $15.0M |
| Other Current | $2.7M |
| Total Current Assets | $285.6M |
| PP&E (Net) | $6.4M |
| Long-term Investments | $415.0K |
| Total Non-current Assets | $6.8M |
| Total Assets | $292.4M |
Analysis
Selected assets total $292.4M for Latest. The largest visible component is Cash & Equivalents at $267.8M, about 91.6% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Competitors
Peer companies in the same sector
No competitor data available.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 2, 2026 | |
| 8-K | Current report | Oct 27, 2026 | |
| 8-K/A | 8-K/A filing | Oct 9, 2026 |
How much cash does RNA have?
Atrium Therapeutics, Inc. (RNA) reported $270.00M in cash and equivalents in fiscal 2025.
How much debt does RNA carry?
Atrium Therapeutics, Inc. (RNA) reported $3.67M of total debt, with net debt of -$266.33M.
Continue the stock analysis
Jump to another research area for this company.